Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of NNC0480-0389 and Semaglutide in Healthy Chinese Men
NCT05498610Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2022
- Primary completion
- Oct 2022
- Modality
- Recombinant Proteins and Enzymes, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised trial of NNC0480-0389 in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Novo Nordisk. Primary endpoints: Area under the plasma concentration-time curve from time 0 to infinity at Day 43 and Maximum plasma concentration at Day 43. Started Aug 2022; status: completed.
02
Drugs
NNC0480-0389
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05498610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05498610.